UBS Group AG Raises Stock Position in Caris Life Sciences, Inc. $CAI

Key Points

• UBS Group AG massively increased its Caris Life Sciences stake by 825.9% in Q4, acquiring an additional 1,948,107 shares to hold 2,183,980 shares (about 0.77% of the company) worth roughly $58.9 million.
• Analyst coverage is mixed with a consensus rating of Hold and an average price target of $28.86; four analysts rate the stock Buy, two Hold and one Sell, while firms like Jefferies and Goldman Sachs have recently started coverage with Buy ratings and ~$27–$28 targets.
• Caris reported a Q4 beat—$0.28 EPS vs. $0.01 expected and revenue of $292.9M, up 125.4% year-over-year—and the shares trade around $18.95 with a market cap near $5.36 billion.

UBS Group AG lifted its stake in shares of Caris Life Sciences, Inc. (NASDAQ:CAI - Free Report) by 825.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,183,980 shares of the company's stock after acquiring an additional 1,948,107 shares during the quarter. UBS Group AG owned approximately 0.77% of Caris Life Sciences worth $58,924,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Olistico Wealth LLC purchased a new position in shares of Caris Life Sciences during the fourth quarter worth approximately $31,000. GF Fund Management CO. LTD. bought a new position in shares of Caris Life Sciences during the fourth quarter valued at approximately $150,000. Courier Capital LLC bought a new position in shares of Caris Life Sciences during the fourth quarter valued at approximately $231,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Caris Life Sciences during the fourth quarter valued at approximately $370,000. Finally, Diversified Trust Co. bought a new position in shares of Caris Life Sciences during the fourth quarter valued at approximately $540,000.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on CAI shares. Wall Street Zen downgraded shares of Caris Life Sciences from a "buy" rating to a "hold" rating in a research note on Saturday. Canaccord Genuity Group dropped their price objective on shares of Caris Life Sciences from $30.00 to $22.00 and set a "hold" rating on the stock in a research note on Friday, March 13th. Jefferies Financial Group started coverage on shares of Caris Life Sciences in a research note on Monday, April 13th. They set a "buy" rating and a $28.00 price objective on the stock. The Goldman Sachs Group started coverage on shares of Caris Life Sciences in a research note on Wednesday, April 1st. They set a "buy" rating and a $27.00 price objective on the stock. Finally, Robert W. Baird increased their price objective on shares of Caris Life Sciences from $26.00 to $28.00 and gave the company an "outperform" rating in a research note on Friday, February 27th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $28.86.

Caris Life Sciences Stock Up 1.4%

Shares of CAI opened at $18.95 on Wednesday. The firm has a market capitalization of $5.36 billion and a P/E ratio of -105.28. Caris Life Sciences, Inc. has a twelve month low of $16.28 and a twelve month high of $42.50. The company has a current ratio of 7.85, a quick ratio of 7.35 and a debt-to-equity ratio of 0.66. The company has a 50 day moving average price of $19.09.

Caris Life Sciences (NASDAQ:CAI - Get Free Report) last announced its earnings results on Thursday, February 26th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.27. The firm had revenue of $292.89 million during the quarter, compared to analyst estimates of $281.00 million. Caris Life Sciences's revenue was up 125.4% on a year-over-year basis. During the same quarter last year, the business earned ($1.73) earnings per share. On average, sell-side analysts expect that Caris Life Sciences, Inc. will post 0.12 EPS for the current year.

About Caris Life Sciences

Caris Life Sciences NASDAQ: CAI is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.

Want to see what other hedge funds are holding CAI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Caris Life Sciences, Inc. (NASDAQ:CAI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.